Intellia Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| 0JBU.L | CRSP | EDIT | DTIL | SCTX | PRQR | |
|---|---|---|---|---|---|---|
| Market cap | — | 3.79B | 253.12M | 282.46M | 228.58M | 146.98M |
| P/E (TTM) | — | — | — | 29.6 | — | — |
| Forward P/E | — | -10.6 | -2.3 | -3.4 | -3.6 | -2.3 |
| Price/book | 2.3 | 2.3 | 3.0 | 4.0 | 1.8 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +11.61% | −22.50% | −29.34% | +38.20% | −30.31% | −52.73% |
| Today | +10.63% | +0.44% | −4.09% | +7.09% | −8.70% | −0.95% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 0JBU.L news ›Intellia Therapeutics (NTLA) Emerges as a Bright Spot Amid Tech Selloff
Intellia Therapeutics Inc. (NASDAQ:NTLA) is one of the 10 Stocks With Monster Gains Amid Market Turmoil. Intellia Therapeutics snapped a three-day losing streak on Friday, jumping 5.04 percent to finish at $10 apiece, as investor funds…
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today…
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals Poster presentations to include patient perspective…
Intellia Therapeutics (NTLA) Receives a Buy from Canaccord Genuity
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Intellia Therapeutics on November 13 and set a price target of $49.00. The company’s shares closed last Friday at $9.70. According to TipRanks, Ijem is a 5-star analyst with…
Head to Head Review: Intellia Therapeutics (NASDAQ:NTLA) versus Ionis Pharmaceuticals (NASDAQ:IONS)
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) and Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of…
Intellia Therapeutics’ One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
Intellia Therapeutics (NASDAQ:NTLA) presented additional clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema, as the company awaits a U.S. regulatory decision.…
Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript
Transcripts Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript Nov 12, 2026, 7:18 PM ETIntellia Therapeutics, Inc. (NTLA) StockSA Transcripts163.01K Followers Intellia…
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference 2026 in London
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 6, 2026
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Intellia Therapeutics (NASDAQ:NTLA) Posts Quarterly Earnings Results
Posted by Kim Johansen on Nov 7th, 2026 Shares of NTLA traded up $0.25 during trading hours on Friday, reaching $11.35. 4,402,763 shares of the stock traded hands, compared to its average volume of 5,430,535. The company’s 50-day moving…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com11
- markets.businessinsider.com8
- themarketsdaily.com4
- biospace.com2
- investingnews.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 31 articles, not a forecast.